[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100545626":3},{"organization":4,"armGroups":7,"interventions":37,"overallOfficials":43,"centralContacts":52,"locations":58,"responsibleParty":348,"collaborators":350,"id":353,"slug":354,"hasResults":355,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":43,"eligibilityCriteria":359,"healthyVolunteers":355,"sex":360,"minAge":361,"maxAge":43,"enrollmentInfo":362,"targetDuration":43,"studyType":365,"phases":366,"briefSummary":368,"conditions":369,"keywords":43,"overallStatus":61,"whyStopped":43,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":372,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":379,"locationsCount":380},{"fullName":5,"class":6},"MediLink Therapeutics (Suzhou) Co., Ltd.","INDUSTRY",[8,14,18,22,27,31],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1","EXPERIMENTAL","YL211 Monotherapy Dose Esclation",[13],"Drug: YL211",{"label":15,"type":10,"description":16,"interventionNames":17},"Part 2","YL211 Monotherapy Backfill",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Part 3","YL211 Monotherapy Dose Expansion",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Part 4","YL211 + Pembro Combination Therapy Dose Esclation",[26],"Drug: YL211+Pembrolizumab",{"label":28,"type":10,"description":29,"interventionNames":30},"Part 5","YL211 + Pembro Combination Therapy Backfill",[26],{"label":32,"type":33,"description":34,"interventionNames":35},"Part 6","ACTIVE_COMPARATOR","YL211 + Pembro Combination Therapy or Pembro + Chemo Combination Therapy Dose Expansion",[36],"Drug: YL211 + Pembro or Pembro+ Pemetrexed + (Carboplatin or Cisplatin)",[38,44,48],{"type":39,"name":40,"description":41,"armGroupLabels":42,"otherNames":43},"DRUG","YL211","Patients will be treated with YL211 intravenous (IV) infusion only.",[9,15,19],null,{"type":39,"name":45,"description":46,"armGroupLabels":47,"otherNames":43},"YL211+Pembrolizumab","Patients will be treated with YL211 and Pembro by infusion.",[23,28],{"type":39,"name":49,"description":50,"armGroupLabels":51,"otherNames":43},"YL211 + Pembro or Pembro+ Pemetrexed + (Carboplatin or Cisplatin)","participants will receive therapy YL211 + Pembro or Pembro+ Pemetrexed + (Carboplatin or Cisplatin) by infusion.(Part 6)",[32],[53],{"name":54,"role":55,"phone":56,"phoneExt":43,"email":57},"MediLink Study Team","CONTACT","+86 0512-62858368","clinicaltrials@medilinkthera.com",[59,80,94,110,126,141,154,166,180,188,203,214,228,240,253,268,282,296,308,319,332],{"facility":60,"status":61,"city":62,"state":63,"zip":64,"country":65,"countryCode":66,"cosmosGeoPoint":67,"geoPoint":72,"contacts":73},"University of Colorado Hospital - Anschutz Cancer Pavilion","RECRUITING","Aurora","Colorado","80045","United States","US",{"type":68,"coordinates":69},"Point",[70,71],-104.83192,39.72943,{"lat":71,"lon":70},[74,77],{"name":75,"role":55,"phone":43,"phoneExt":43,"email":76},"Ashley Fisher","ASHLEY.R.FISHER@CUANSCHUTZ.EDU",{"name":78,"role":79,"phone":43,"phoneExt":43,"email":43},"Antonio Jimeno","PRINCIPAL_INVESTIGATOR",{"facility":81,"status":61,"city":82,"state":63,"zip":83,"country":65,"countryCode":66,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"Sarah Cannon Research Institute (SCRI) at HealthONE","Denver","80218-1238",{"type":68,"coordinates":85},[86,87],-104.9847,39.73915,{"lat":87,"lon":86},[90,93],{"name":91,"role":55,"phone":43,"phoneExt":43,"email":92},"Jason Henry","Jason.Henry2@sarahcannon.com",{"name":91,"role":79,"phone":43,"phoneExt":43,"email":43},{"facility":95,"status":61,"city":96,"state":97,"zip":98,"country":65,"countryCode":66,"cosmosGeoPoint":99,"geoPoint":103,"contacts":104},"Yale School of Medicine - Yale Cancer Center - Smilow Cancer Hospital Care Centers - North Haven","North Haven","Connecticut","06473-2142",{"type":68,"coordinates":100},[101,102],-72.85954,41.39093,{"lat":102,"lon":101},[105,108],{"name":106,"role":55,"phone":43,"phoneExt":43,"email":107},"Anastasio Gabrielle","gabrielle.anastasio@yale.edu",{"name":109,"role":79,"phone":43,"phoneExt":43,"email":43},"Michael Cecchini",{"facility":111,"status":61,"city":112,"state":113,"zip":114,"country":65,"countryCode":66,"cosmosGeoPoint":115,"geoPoint":119,"contacts":120},"Sarah Cannon Research Institute at Florida Cancer Specialists","Orlando","Florida","32827",{"type":68,"coordinates":116},[117,118],-81.37924,28.53834,{"lat":118,"lon":117},[121,124],{"name":122,"role":55,"phone":43,"phoneExt":43,"email":123},"Elizabeth Gilmore","Elizabeth.Griffith@scri.com",{"name":125,"role":79,"phone":43,"phoneExt":43,"email":43},"Cesar Perez",{"facility":127,"status":61,"city":128,"state":113,"zip":129,"country":65,"countryCode":66,"cosmosGeoPoint":130,"geoPoint":134,"contacts":135},"Florida Cancer Specialists & Research Institute (FCS) - Sarasota Cattlemen Office","Sarasota","34232-6422",{"type":68,"coordinates":131},[132,133],-82.53065,27.33643,{"lat":133,"lon":132},[136,139],{"name":137,"role":55,"phone":43,"phoneExt":43,"email":138},"Carly Taylor","ctaylor@flcancer.com",{"name":140,"role":79,"phone":43,"phoneExt":43,"email":43},"Manish Patel",{"facility":142,"status":61,"city":143,"state":144,"zip":145,"country":65,"countryCode":66,"cosmosGeoPoint":146,"geoPoint":150,"contacts":151},"Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley","Las Vegas","Nevada","89169",{"type":68,"coordinates":147},[148,149],-115.13722,36.17497,{"lat":149,"lon":148},[152],{"name":153,"role":55,"phone":43,"phoneExt":43,"email":43},"site coordinator",{"facility":155,"status":61,"city":156,"state":157,"zip":158,"country":65,"countryCode":66,"cosmosGeoPoint":159,"geoPoint":163,"contacts":164},"University of Cincinnati Vontz Center for Molecular Studies","Cincinnati","Ohio","45219",{"type":68,"coordinates":160},[161,162],-84.51439,39.12711,{"lat":162,"lon":161},[165],{"name":153,"role":55,"phone":43,"phoneExt":43,"email":43},{"facility":167,"status":61,"city":168,"state":169,"zip":170,"country":65,"countryCode":66,"cosmosGeoPoint":171,"geoPoint":175,"contacts":176},"The University of Texas - MD Anderson Cancer Center","Houston","Texas","77030",{"type":68,"coordinates":172},[173,174],-95.36327,29.76328,{"lat":174,"lon":173},[177],{"name":178,"role":55,"phone":43,"phoneExt":43,"email":179},"Coordinator Clinical operation director","RA@medilinkthera.com",{"facility":181,"status":61,"city":168,"state":169,"zip":182,"country":65,"countryCode":66,"cosmosGeoPoint":183,"geoPoint":185,"contacts":186},"NEXT Oncology - Houston","77055",{"type":68,"coordinates":184},[173,174],{"lat":174,"lon":173},[187],{"name":153,"role":55,"phone":43,"phoneExt":43,"email":43},{"facility":189,"status":61,"city":190,"state":169,"zip":191,"country":65,"countryCode":66,"cosmosGeoPoint":192,"geoPoint":196,"contacts":197},"NEXT Oncology - Dallas","Irving","75039",{"type":68,"coordinates":193},[194,195],-96.94889,32.81402,{"lat":195,"lon":194},[198,201],{"name":199,"role":55,"phone":43,"phoneExt":43,"email":200},"Erica Torres","etorres@nextoncology.com",{"name":202,"role":79,"phone":43,"phoneExt":43,"email":43},"Shiraj Sen",{"facility":204,"status":61,"city":205,"state":169,"zip":206,"country":65,"countryCode":66,"cosmosGeoPoint":207,"geoPoint":211,"contacts":212},"NEXT San Antonio","San Antonio","78229",{"type":68,"coordinates":208},[209,210],-98.49363,29.42412,{"lat":210,"lon":209},[213],{"name":178,"role":55,"phone":43,"phoneExt":43,"email":179},{"facility":215,"status":61,"city":216,"state":217,"zip":218,"country":219,"countryCode":220,"cosmosGeoPoint":221,"geoPoint":225,"contacts":226},"Gosford Hospital","Gosford","New South Wales","2250","Australia","AU",{"type":68,"coordinates":222},[223,224],151.34399,-33.4244,{"lat":224,"lon":223},[227],{"name":153,"role":55,"phone":43,"phoneExt":43,"email":43},{"facility":229,"status":61,"city":230,"state":231,"zip":232,"country":219,"countryCode":220,"cosmosGeoPoint":233,"geoPoint":237,"contacts":238},"One Clinical Research - Nedlands","Nedlands","Western Australia","6009",{"type":68,"coordinates":234},[235,236],115.8073,-31.98184,{"lat":236,"lon":235},[239],{"name":153,"role":55,"phone":43,"phoneExt":43,"email":43},{"facility":241,"status":61,"city":242,"state":43,"zip":43,"country":219,"countryCode":220,"cosmosGeoPoint":243,"geoPoint":247,"contacts":248},"Monash Health","Melbourne",{"type":68,"coordinates":244},[245,246],144.96332,-37.814,{"lat":246,"lon":245},[249,252],{"name":250,"role":55,"phone":43,"phoneExt":43,"email":251},"Sophia Frentzas","sophia.frentzas@monash.edu",{"name":250,"role":79,"phone":43,"phoneExt":43,"email":43},{"facility":254,"status":61,"city":255,"state":255,"zip":43,"country":256,"countryCode":257,"cosmosGeoPoint":258,"geoPoint":262,"contacts":263},"Princess Margaret Hospital","Toronto","Canada","CA",{"type":68,"coordinates":259},[260,261],-79.39864,43.70643,{"lat":261,"lon":260},[264,267],{"name":265,"role":55,"phone":43,"phoneExt":43,"email":266},"Albiruni Razak","Albiruni.razak@uhn.ca",{"name":265,"role":79,"phone":43,"phoneExt":43,"email":43},{"facility":269,"status":61,"city":270,"state":43,"zip":43,"country":256,"countryCode":257,"cosmosGeoPoint":271,"geoPoint":275,"contacts":276},"The Ottawa Hospital - General Campus","Ottawa",{"type":68,"coordinates":272},[273,274],-75.69812,45.41117,{"lat":274,"lon":273},[277,280],{"name":278,"role":55,"phone":43,"phoneExt":43,"email":279},"Jura Nakamura","junakamura@ohri.ca",{"name":281,"role":79,"phone":43,"phoneExt":43,"email":43},"Scott Laurie",{"facility":283,"status":61,"city":284,"state":285,"zip":286,"country":287,"countryCode":288,"cosmosGeoPoint":289,"geoPoint":293,"contacts":294},"China-Japan Friendship Hospital","Beijing","Beijing Municipality","100029","China","CN",{"type":68,"coordinates":290},[291,292],116.39723,39.9075,{"lat":292,"lon":291},[295],{"name":153,"role":55,"phone":43,"phoneExt":43,"email":43},{"facility":297,"status":61,"city":298,"state":299,"zip":300,"country":287,"countryCode":288,"cosmosGeoPoint":301,"geoPoint":305,"contacts":306},"The First Affiliated Hospital - Zhejiang University School of Medicine","Hangzhou","Zhejiang","310003",{"type":68,"coordinates":302},[303,304],120.16142,30.29365,{"lat":304,"lon":303},[307],{"name":153,"role":55,"phone":43,"phoneExt":43,"email":43},{"facility":309,"status":61,"city":310,"state":299,"zip":311,"country":287,"countryCode":288,"cosmosGeoPoint":312,"geoPoint":316,"contacts":317},"Wenzhou Medical University - The First Affiliated Hospital","Wenzhou","325000",{"type":68,"coordinates":313},[314,315],120.66682,27.99942,{"lat":315,"lon":314},[318],{"name":153,"role":55,"phone":43,"phoneExt":43,"email":43},{"facility":320,"status":61,"city":321,"state":43,"zip":43,"country":287,"countryCode":288,"cosmosGeoPoint":322,"geoPoint":326,"contacts":327},"West China Hospital, Sichuan University","Chengdu",{"type":68,"coordinates":323},[324,325],104.06667,30.66667,{"lat":325,"lon":324},[328,331],{"name":329,"role":55,"phone":43,"phoneExt":43,"email":330},"Yan Zhang","18980601166@qq.com",{"name":329,"role":79,"phone":43,"phoneExt":43,"email":43},{"facility":333,"status":61,"city":334,"state":43,"zip":43,"country":287,"countryCode":288,"cosmosGeoPoint":335,"geoPoint":339,"contacts":340},"Sun Yat-sen University Cancer Center","Guangzhou",{"type":68,"coordinates":336},[337,338],113.25,23.11667,{"lat":338,"lon":337},[341,344,346],{"name":342,"role":55,"phone":43,"phoneExt":43,"email":343},"Danyun Ruan","ruandy1@sysucc.org.cn",{"name":345,"role":79,"phone":43,"phoneExt":43,"email":43},"Ruihua Xu",{"name":342,"role":347,"phone":43,"phoneExt":43,"email":43},"SUB_INVESTIGATOR",{"type":349,"investigatorFullName":43,"investigatorTitle":43,"investigatorAffiliation":43,"oldNameTitle":43,"oldOrganization":43},"SPONSOR",[351],{"name":352,"class":6},"Hoffmann-La Roche","100545626","phase-1-safetytolerability-pharmacokinetics-and-efficacy-of-yl211-in-patients-with-advanced-solid-tumors-100545626",false,"NCT06384352","Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors","A Phase 1, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors","Inclusion Criteria:\n\n1. Informed of the trial before the start of the trial and voluntarily sign their name and date on the ICF.\n2. Aged ≥18 years.\n3. Be able and willing to comply with protocol visits and procedures.\n4. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or\n5. Adequate organ and bone marrow function.\n\nFor Part 1: History of an advanced solid tumors (including locally advanced unresectable or metastatic NSCLC, metastatic colorectal carcinoma (mCRC), advanced gastric adenocarcinoma (GAC)\u002F gastroesophageal junction adenocarcinoma (GEJA), pancreatic ductal adenocarcinoma (PDAC), hepatocellular carcinoma (HCC), intrahepatic biliary tract cancer (ih-BTC), and head and neck squamous cell carcinoma (HNSCC) who failed currently available standard therapies and are not amenable to surgical resection, or for whom no available standard therapy or no other approved therapeutic options that have demonstrated clinical benefit.\n\nFor Part 2: For patients with CRC: History of histologically or cytologically confirmed diagnosis of metastatic CRC and at least 2 prior regimens of standard treatment For patients with NSCLC: History of histologically or cytologically confirmed diagnosis of locally advanced unresectable or metastatic NSCLC and no more than 2 lines of prior cytotoxic systemic therapy in the locally advanced or metastatic setting.\n\nFor Part 3: History of histologically or cytologically confirmed diagnosis of locally advanced unresectable or metastatic non-squamous (Part 3A) or squamous (Part 3B) NSCLC and no more than 2 lines of prior systemic therapy\n\nFor Part 4: History of histologically or cytologically confirmed diagnosis of locally advanced unresectable or metastatic non-squamous NSCLC who have progressed on or after 1 or 2 prior lines of systemic therapy\n\nFor Part 5 and Part 6 Histologically or cytologically documented locally advanced unresectable or metastatic non-squamous NSCLC that is not eligible for curative surgery and\u002For definitive chemoradiotherapy and no prior systemic treatment for advanced unresectable or metastatic NSCLC\n\nExclusion Criteria:\n\n1. Prior treatment with an agent targeting c-MET (including antibody, ADC, chimeric antigen receptor T cell \\[CAR-T\\], and other drugs) with the exception of prior treatment with MET-targeted TKIs which are allowed.\n2. Previously received an ADC consisting of a TopoI\n3. Received continuous systemic steroids therapy for more than 28 days or require long-term (≥ 28 days) use of systemic steroids therapy within 28 days before the first administration, or have other acquired or congenital immune deficiency diseases. (Note: The protocol lists specific situational exceptions immediately following this clause).\n4. A history of leptomeningeal carcinomatosis or carcinomatous meningitis\n5. Brain metastasis, except for the following situations:\n\n   Participants with asymptomatic brain metastasis who do not require immediate local or systemic treatment (such as mannitol or steroids, surgery, or radiotherapy) are allowed to be enrolled If the participant's brain metastasis is treated and the condition of the metastasis is stable (brain imaging examination at least 2 weeks before the first administration shows that the lesion is stable, there is no evidence of new or original brain metastasis enlargement, there are no new neurological symptoms, and immediate local or systemic treatment is not required), admission is allowed\n6. Clinically significant concomitant pulmonary disease, including but not limited to:\n\nA history of drug-induced pneumonitis A history of (non-infectious) interstitial lung disease (ILD)\u002Fpneumonitis that requires steroids, current ILD\u002Fpneumonitis, or where suspected ILD\u002Fpneumonitis cannot be ruled out by imaging at screening","ALL","18 Years",{"count":363,"type":364},500,"ESTIMATED","INTERVENTIONAL",[367],"PHASE1","This is a multicenter, open-label, Phase 1 study. The study will enroll subjects with advanced solid tumors. It consists of six parts. Objectives for Dose-Escalation Parts (Part 1 and Part 4) To evaluate the safety and tolerability of YL211 as monotherapy in patients with selected advanced solid tumors (Part 1) and in combination with pembrolizumab in patients with second or third line locally advanced unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) (Part 4) To determine the maximum tolerated dose (MTD) and select the recommended expansion dose(s) (RED(s)) of YL211 as monotherapy in patients with advanced solid tumors (Part 1) and in combination with pembrolizumab in patients with second line locally advanced unresectable or metastatic non-squamous NSCLC (Part 4) Objectives for Backfill Enrollment Parts (Part 2 and Part 5) To better estimate and characterize the safety and efficacy of YL211 as monotherapy in patients with metastatic colorectal cancer (mCRC) or locally advanced unresectable or metastatic NSCLC (Part 2) and in combination with pembrolizumab in patients with previously untreated locally advanced unresectable or metastatic non-squamous NSCLC (Part 5) To select the RED(s) of YL211 as monotherapy in patients with metastatic colorectal cancer (mCRC) or locally advanced unresectable or metastatic NSCLC (Part 2) and in combination with pembrolizumab in patients with previously untreated locally advanced unresectable or metastatic non-squamous NSCLC (Part 5) Objectives for the Dose-Expansion Parts (Part 3 and Part 6) To further characterize the safety and efficacy of YL211 as monotherapy (Part 3) in patients with locally advanced unresectable or metastatic non-squamous or squamous NSCLC and in combination with pembrolizumab in patients with previously untreated locally advanced unresectable or metastatic non- squamous NSCLC (Part 6) To compare the clinical activity of YL211 in combination with pembrolizumab against pembrolizumab, pemetrexed, and platinum-based chemotherapy (cisplatin or carboplatin) in participants with previously untreated advanced unresectable or metastatic non-squamous NSCLC (Part 6)",[370],"Advanced Solid Tumors","2026-06-24",{"date":373,"type":374},"2026-06-29","ACTUAL",{"date":376,"type":374},"2024-05-01",{"date":378,"type":364},"2031-06-30",{"name":5,"class":6},21]